Shares of Veracyte Inc (NASDAQ:VCYT) reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $15.50 and last traded at $14.87, with a volume of 19188 shares. The stock had previously closed at $14.01.

Several analysts have issued reports on VCYT shares. ValuEngine upgraded Veracyte from a “buy” rating to a “strong-buy” rating in a report on Friday, October 12th. BidaskClub downgraded Veracyte from a “strong-buy” rating to a “buy” rating in a report on Friday, September 7th. Piper Jaffray Companies boosted their price objective on Veracyte to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, July 24th. Janney Montgomery Scott upgraded Veracyte from a “neutral” rating to a “buy” rating in a report on Wednesday, October 31st. Finally, William Blair restated an “outperform” rating on shares of Veracyte in a report on Tuesday, October 30th. Two research analysts have rated the stock with a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $12.33.

The firm has a market cap of $567.95 million, a price-to-earnings ratio of -15.91 and a beta of 0.74. The company has a debt-to-equity ratio of 0.32, a current ratio of 9.14 and a quick ratio of 8.81.

Veracyte (NASDAQ:VCYT) last issued its earnings results on Monday, October 29th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.13. The company had revenue of $23.47 million for the quarter, compared to the consensus estimate of $21.52 million. Veracyte had a negative return on equity of 65.73% and a negative net margin of 33.00%. On average, equities research analysts expect that Veracyte Inc will post -0.69 earnings per share for the current year.

In other news, insider Christopher M. Hall sold 40,000 shares of the company’s stock in a transaction dated Wednesday, October 31st. The stock was sold at an average price of $13.51, for a total value of $540,400.00. Following the transaction, the insider now owns 35,955 shares in the company, valued at approximately $485,752.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Bonnie H. Anderson sold 6,000 shares of the company’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $12.00, for a total value of $72,000.00. Following the completion of the transaction, the chairman now owns 58,541 shares in the company, valued at approximately $702,492. The disclosure for this sale can be found here. 13.70% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its stake in shares of Veracyte by 15.7% in the 3rd quarter. Wells Fargo & Company MN now owns 43,349 shares of the biotechnology company’s stock valued at $415,000 after buying an additional 5,885 shares in the last quarter. Meeder Asset Management Inc. grew its stake in shares of Veracyte by 79.8% in the 3rd quarter. Meeder Asset Management Inc. now owns 16,178 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 7,182 shares in the last quarter. Engineers Gate Manager LP grew its stake in shares of Veracyte by 38.4% in the 3rd quarter. Engineers Gate Manager LP now owns 34,214 shares of the biotechnology company’s stock valued at $327,000 after buying an additional 9,495 shares in the last quarter. Essex Investment Management Co. LLC grew its stake in shares of Veracyte by 3.5% in the 3rd quarter. Essex Investment Management Co. LLC now owns 315,286 shares of the biotechnology company’s stock valued at $3,011,000 after buying an additional 10,531 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Veracyte in the 3rd quarter valued at approximately $127,000. 83.03% of the stock is owned by institutional investors and hedge funds.

WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2018/11/10/veracyte-vcyt-sets-new-1-year-high-at-15-50.html.

Veracyte Company Profile (NASDAQ:VCYT)

Veracyte, Inc operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Featured Article: The risks of owning bonds

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.